Abstract
Multiple sclerosis is an inflammatory demyelinating and neurodegenerative disorder of the central nervous system (CNS). The primary cause of the disease remains unknown, but an altered immune regulation with features of autoimmunity has generally been considered to play a critical role in the pathogenesis. Historically, lesion development has been attributed to activation of CD4 and CD8 T lymphocytes, B lymphocytes, and monocytes in the peripheral circulation and the migration of these cells through the blood–brain barrier to exert direct or indirect cytotoxic effects on myelin, oligodendrocytes and neuronal processes in the CNS. This broadly accepted concept was significantly influenced by the experimental autoimmune encephalitis (EAE) model, in which either immunization with myelin antigens or injection of a myelin antigen-specific T cell line into a recipient results in inflammatory demyelination in the CNS. More recent studies reveal that the loss of oligodendrocytes and neurons begins in the earliest stages of the disease and may not always be associated with blood-derived inflammatory cells. The pathology affects both the white and the gray matters and the clinical disability best correlates with the overall neurodegenerative process. These newer observations prompted several revisions of the classical concept of MS and facilitated a shift from using EAE to using other model systems. This chapter summarizes the classical and more contemporary concepts of MS, and provides methodologies for employing the cuprizone model for further explorations of the pathogenesis and treatment of the disease.
Key words
- Multiple sclerosis
- Autoimmunity
- Oligodendrocytopathy
- Demyelination
- Cuprizone model
- Mitochondrion
- Apoptosis
- Histological methods
- Gene expression quantitation
This is a preview of subscription content, access via your institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Bennett JL, Stüve O (2009) Update on inflammation, neurodegeneration, and immunoregulation in multiple sclerosis: therapeutic implications. Clin Neuropharmacol 32(3):121–132
Linthicum DS, Munoz JJ, Blaskett A (1982) Acute experimental autoimmune encephalomyelitis in mice. I. Adjuvant action of Bordetella pertussis is due to vasoactive amine sensitization and increased vascular permeability of the central nervous system. Cell Immunol 73(2):299–310
Westarp ME, Wekerle H, Ben-Nun A et al (1987) T lymphocyte line-mediated experimental allergic encephalomyelitis – a pharmacologic model for testing of immunosuppressive agents for the treatment of autoimmune central nervous system disease. J Pharmacol Exp Ther 242(2):614–620
Steinman L (2010) Mixed results with modulation of TH-17 cells in human autoimmune diseases. Nat Immunol 11(1):41–44
Crome SQ, Wang AY, Levings MK (2010) Translational mini-review series on TH17 cells: function and regulation of human T helper 17 cells in health and disease. Clin Exp Immunol 159(2):109–119
O’Connor RA, Taams LS, Anderton SM (2010) Translational mini-review series on Th17 cells: CD4 T helper cells: functional plasticity and differential sensitivity to regulatory T cell-mediated regulation. Clin Exp Immunol 159(2):137–147
Correale J, Villa A (2010) Role of regulatory CD8+CD25+FoxP3+ T cells in multiple sclerosis. Ann Neurol 67(5):625–638
Cepok S, Rosche B, Grummel V et al (2005) Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis. Brain 128:1667–1676
Qin Y, Duquette P, Zhang Y et al (1998) Clonal expansion and somatic hypermutation of Vh genes of B cells from the cerebrospinal fluid in multiple sclerosis. J Clin Invest 102:1045–1050
Owens GP, Burgoon MP, Anthony J et al (2001) The immunoglobulin G heavy chain repertoire in multiple sclerosis plaques is distinct from the heavy chain repertoire in peripheral blood lymphocytes. Clin Immunol 98:258–263
Monson NL, Brezinschek HP, Brezinschek RI et al (2005) Receptor revision and atypical mutational characteristics in clonally expanded B cells from the cerebrospinal fluid of recently diagnosed multiple sclerosis patients. J Neuroimmunol 158(1–2):170–181
Lambracht-Washington D, O’Connor KC, Cameron EM et al (2007) Antigen specificity of clonally expanded and receptor edited cerebrospinal fluid B cells from patients with relapsing remitting MS. J Neuroimmunol 186(1–2):164–176
Serafini B, Rosicarelli B, Magliozzi R et al (2004) Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol 14(2):164–174
Willis SN, Stadelmann C, Rodig SJ et al (2009) Epstein–Barr virus infection is not a characteristic feature of multiple sclerosis brain. Brain 132(Pt 12):3318–3328
Lucchinetti C, Brück W, Noseworthy J (2001) Multiple sclerosis: recent developments in neuropathology, pathogenesis, magnetic resonance imaging studies and treatment. Curr Opin Neurol 14(3):259–269
Stoeckle C, Tolosa E (2009) Antigen processing and presentation in multiple sclerosis. Results Probl Cell Differ 2010;51:149–172
Goodin DS, Cohen BA, O’Connor P et al (2008) Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 71(10):766–773
Hauser SL, Waubant E, Arnold DL et al (2008) HERMES Trial Group. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 358(7):676–688
Bar-Or A, Calabresi PA, Arnold D et al (2008) Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol 63(3):395–400
Trapp BD, Peterson J, Ransohoff RM et al (1998) Axonal transection in the lesions of multiple sclerosis. N Engl J Med 338:278–285
Trapp BD, Bo L, Mork S, Chang A (1999) Pathogenesis of tissue injury in MS lesions. J Neuroimmunol 98:49–56
Peterson JW, Bo L, Mork S, Chang A et al (2002) VCAM-1-positive microglia target oligodendrocytes at the border of multiple sclerosis lesions. J Neuropathol Exp Neurol 61:539–546
Kutzelnigg A, Lucchinetti CF, Stadelmann C (2005) Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 128(Pt 11):2705–2712
Lucchinetti C, Brück W, Parisi J et al (2000) Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 47(6):707–717
Barnett MH, Prineas JW (2004) Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann Neurol 55:458–468
Henderson AP, Barnett MH, Parratt JD, Prineas JW et al (2009) Multiple sclerosis: distribution of inflammatory cells in newly forming lesions. Ann Neurol 66:739–753
Barnett MH, Sutton I (2006) The pathology of multiple sclerosis: a paradigm shift. Curr Opin Neurol 19:242–247
Breij EC, Brink BP, Veerhuis R et al (2008) Homogeneity of active demyelinating lesions in established multiple sclerosis. Ann Neurol 63(1):16–25
Peterson JW, Bo L, Mork S et al (2001) Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol 50:389–400
Vercellino M, Plano F, Votta B et al (2005) Grey matter pathology in multiple sclerosis. J Neuropathol Exp Neurol 64:1101–1107
Wegener C, Esiri MM, Chance SA et al (2006) Neocortical neuronal, synaptic, and glial loss in multiple sclerosis. Neurology 67:960–967
Zipp F (2000) Apoptosis in multiple sclerosis. Cell Tissue Res 301(1):163–171
Hestvik AL, Skorstad G, Vartdal F et al (2009) Idiotype-specific CD4+ T cell induced apoptosis of human oligodendrocytes. J Autoimmun 32(2):125–132
Lu F, Selak M, O’Connor J et al (2000) Oxidative damage to mitochondrial DNA and activity of mitochondrial enzymes in lesions of multiple sclerosis. J Neurol Sci 177:95–103
Kalman B, Albert RH, Leist TP (2002) Genetics of multiple sclerosis: determinants of autoimmunity and neurodegeneration. Autoimmunity 35(4):225–234
Kalman B, Laitinen K, Komoly S (2007) The involvement of mitochondria in the pathogenesis of multiple sclerosis. J Neuroimmunol 188(1–2):1–12
Kalman B (2006) Role of Mitochondria in MS. Curr Neurol Neurosci Rep 6:244–252
Bo L, Dawson TM, Wesselingh S et al (1994) Induction of nitric oxide synthase in demyelinating regions of multiple sclerosis brains. Ann Neurol 36:778–786
Cross AH, Manning PT, Stern MK et al (1997) Evidence for the production of peroxynitrite in inflammatory CNS demyelination. J Neuroimmunol 80:121–130
Vladimirova O, O’Connor J, Cahill A et al (1998) Oxidative damage to DNA in plaques of MS brains. Mult Scler 4:413–418
Powell T, Sussman JG, Davies-Jones GA (1992) MR imaging in acute multiple sclerosis: ringlike appearance in plaques suggesting the presence of paramagnetic free radicals. Am J Neurorad 13:1544–1546
Hooper DC, Bagasra O, Marini JC et al (1997) Prevention of experimental allergic encephalomyelitis by targeting nitric oxide and peroxinitrite: implications for the treatment of multiple sclerosis. Proc Natl Acad Sci 94:2528–2533
Blokhin A, Vyshkina T, Komoly S et al (2008) Lack of mitochondrial DNA deletions in lesion of multiple sclerosis. Neuromolecular Med 10:187–194
Dutta R, McDonough J, Yin X et al (2006) Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. Ann Neurol 59:478–489
Mahad D, Lassmann H, Turnbull D (2008) Review: mitochondria and disease progression in multiple sclerosis. Neuropathol Appl Neurobiol 34(6):577–589
Mahad DJ, Ziabreva I, Campbell G et al (2009) Mitochondrial changes within axons in multiple sclerosis. Brain 132(Pt 5):1161–1174
Mahad D, Ziabreva I, Lassmann H et al (2008) Mitochondrial defects in acute multiple sclerosis lesions. Brain 131(Pt 7):1722–1735
Trapp BD, Stys PK (2009) Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis. Review. Lancet Neurol 8:280–291
Aboul-Enein F, Lassmann H (2005) Mitochondrial damage and histotoxic hypoxia: a pathway of tissue injury in inflammatory brain disease? Acta Neuropathol (Berl) 109:49–55
Stadelmann C, Ludwin S, Tabira T et al (2005) Tissue preconditioning may explain concentric lesions in Balo’s type of multiple sclerosis. Brain 128:979–987
Graumann U, Reynolds R, Steck AJ et al (2003) Molecular changes in normal appearing white matter in multiple sclerosis are characteristic of neuroprotective mechanisms against hypoxic insult. Brain Pathol 13:554–573
Ludwin SK (1978) Central nervous system demyelination and remyelination in the mouse: an ultrastructural study of cuprizone toxicity. Lab Invest 39:597–612
Matsushima GK, Morell P (2001) The neurotoxicant, cuprizone, as a model to study demyelination and remyelination in the central nervous system. Brain Pathol 11:107–116
Lindner M, Fokuhl J, Linsmeier F et al (2009) Chronic toxic demyelination in the central nervous system leads to axonal damage despite remyelination. Neurosci Lett 453:120–125
Veto S, Acs P, Bauer J et al (2010) Inhibiting poly(ADP-ribose) polymerase: a potential therapy against oligodendrocyte death. Brain 133:822–834
Komoly S (2005) Experimental demyelination caused by primary oligodendrocyte dystrophy. Regional distribution of the lesions in the nervous system of mice [corrected]. Ideggyogy Sz 58:40–43
Kipp M, Clarner T, Dang J (2009) The cuprizone animal model: new insights into an old story. Acta Neuropathol 118:723–736
Remington LT, Babcock AA, Zehntner SP et al (2007) Microglial recruitment, activation, and proliferation in response to primary demyelination. Am J Pathol 170(5):1713–1724
Pasquini LA, Calatayud CA, Bertone Una AL et al (2007) The neurotoxic effect of cuprizone on oligodendrocytes depends on the presence of pro-inflammatory cytokines secreted by microglia. Neurochem Res 32:279–292
Acs P, Kipp M, Norkute A et al (2009) 17b-Estradiol and progesterone prevent cuprizone provoked demyelination of corpus callosum in male mice. Glia 57:807–814
Lindner M, Heine S, Haastert K et al (2008) Sequential myelin protein expression during remyelination reveals fast and efficient repair after central nervous system demyelination. Neuropathol Appl Neurobiol 34:105–114
Armstrong RC (2007) Growth factor regulation of remyelination: behind the growing interest in endogenous cell repair of the CNS. Future Neurol 2:689–697
Morell P, Barrett CV, Mason JL et al (1998) Gene expression in brain during cuprizone-induced demyelination and remyelination. Mol Cell Neurosci 12:220–227
Taylor LC, Gilmore W, Matsushima GK (2009) SJL mice exposed to cuprizone intoxication reveal strain and gender pattern differences in demyelination. Brain Pathol 19:467–479
Hiremath MM, Saito Y, Knapp GW et al (1998) Microglial/macrophage accumulation during cuprizone-induced demyelination in C57BL/6 mice. J Neuroimmunol 92:38–49
Palkovits M (1983) Punch sampling biopsy technique. Methods Enzymol 103:368–376
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media New York
About this protocol
Cite this protocol
Acs, P., Kalman, B. (2012). Pathogenesis of Multiple Sclerosis: What Can We Learn from the Cuprizone Model. In: Perl, A. (eds) Autoimmunity. Methods in Molecular Biology, vol 900. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60761-720-4_20
Download citation
DOI: https://doi.org/10.1007/978-1-60761-720-4_20
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-60761-719-8
Online ISBN: 978-1-60761-720-4
eBook Packages: Springer Protocols